Response to bortezomib in refractory/relapsed multiple myeloma patients: A single center experience with discussion on specific issues

Asia-Pacific Journal of Oncology and Hematology

Volumn 2, Issue 1, 2010, Pages 29-39

  Kyrtsonis, M C ^a   Maltezas, D ^a   Koulieris, E ^a   Zaroulis, C ^b   Tzenou, T ^a   Sachanas, S ^a   Bartzis, V ^a   Georgian, G ^a   Dimou, M ^a   Siakavellas, S ^a   Vassilakopoulos, T P ^a   Anflelopoulou, M K ^a   Koutra, E ^b   Mouzaki, A ^c   Pangalis, G A ^a   Panayiotidis, P ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Neurology Department   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Bortezomib treatment; Multiple myeloma; Neurotoxicity; Observational study; Quality of response; Survival

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; DULOXETINE; FENTANYL; GABAPENTIN; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; PREGABALIN; THALIDOMIDE; VINCRISTINE;

ADD ON THERAPY; ANEMIA; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG ERUPTION; DRUG FEVER; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NERVE FIBER; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; RELAPSE; REVIEW; SENSORY NERVE; SOMNOLENCE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84868148955     PISSN: 17596637     EISSN: 17596645     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Bataille R, Harouseau JL. Multiple myeloma. N Etifll J Med. 1997;336:1657-1664.
2. Engelhardt M, Mettelsmann R.160 years of multiple myeloma. Progress and challenges. Eur J Cancer. 2006;42:1507-1509.
3. Kyle RA. Diagnostic challenges and standard therapy. Semin Hematol. 2001;38:11-14.
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883.
5. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;III: 2516-2520.
6. Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, et al. Immunotherapeutic and immunoregulatory drugs in haematologic malignancies. Curr Topics Med Chem. 2006;6:1657-1686.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348: 2609-2617.
8. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004:127: 165-172.
9. Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
10. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
11. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842-854.
12. Greipp PR, San Miguel J, Durie BG, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
13. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hemopoietic stem cell transplantation. Br J Haematol. 1998; 102:1115-1123.
14. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
15. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio (FLCR) at diagnosis in multiple myeloma (MM). Br J Haematol. 2007;137:240-243.
16. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nero Syst. 2006;1:135-141.
17. Lee KW, Yun T, Song EK, et al. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. J Korean Med Sci. 2005;20: 598-562.
18. Wu KL, Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of Bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematoloflica. 2005;90:996-997.
19. Spicka I, Hajek R, Vytrasova M, et al. Bortezomib (Velcade) in relapsed/ refractory multiple myeloma-the first experience in the Czech Republic. Cas Lek Cesk. 2005;144:638-640.
20. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29:587-590.
21. Musto P, Falcone A, Sanpaolo G, et al. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res. 2005;30:283-285.
22. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica. 2007;92:1149-1150.
23. Suvannasankha A, Smith GG, Juliar BE, Abonour R, Weekly bortezomib/ methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7:131-134.
24. Freimann H, Calderoni A, Cornu P, Olie R, Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Swiss Med Wkly. 2007;137:317-322.
25. Mikhael JR, Belch A, Prince HM, et al. High response rate to bortezomib with or without dexamethase in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009;144:169-175.
26. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Haematologica. 2006;91:929-934.
27. Lee SJ, Richardson PG, Sonneveld P, et al. Bortezomib is associated with better health-related quality of life than high dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2009;143:511-519.
28. Cata JP, Weng HR, Burton AW, Villaeral H, Girald S, Dougherty PM. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007;8:296-306.
29. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neuropathy: a neurophysiologies! and pathological study in the rat Exp Neurol. 2007;204:317-325.
30. Gupta S, Pagliuca A, Devereux S, Mufti GJ, Schey S. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica. 2006; 91:1001.
31. Argyriou AA, Iconomou G, Kalofonos HP, et al. Bortezomib induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;13:27-46.
32. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neuropathy: a neurophysiological and pathological study in the rat Exp Neurol. 2007;204:317-325.
33. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113-3120.
34. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity(Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741-748.
35. Teoh G, Tan D, Hwang W, Koh LP, Chuah C, Ng HJ. Use of immunoglobulin infusions in the management of bortezomib-induced peripheral neuropathy in multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2006;108:Abstract 5097.
36. Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR, Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009;46:110-117.
37. Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia. 2008;22:1933-1937
38. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151-157.
39. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/ refractory multiple myeloma. Leuk Res. 2007;31:779-782.
40. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429-435.
41. Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106:1316-1319.
42. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557-3560.
43. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114:3139-3146.
44. Ladetto M, Donovan JW, Harig S, et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marram Transplant. 2000;6:241-253.
45. Martínez-Sánchez P, Montejano L, Sarasquete ME, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol. 2008;142:766-774.
46. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;iii: 2516-2520.